Basic Information
Zoledronic acid Teva
Regulatory Information
EMEA/H/C/002439
Authorised
August 16, 2012
March 15, 2012
14
October 17, 2024
Company Information
the netherlands
Swensweg 5 2031GA Haarlem
Teva Pharma B.V.
Drug Classification
Generic Medicine
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Zoledronic acid Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Teva.